Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment

Clinical Pharmacology in Drug Development

Volumn 4, Issue 5, 2015, Pages 387-394

  Shilbayeh, Sireen A R ^a   Sy, Sherwin K B ^b   Melhem, Murad ^c   Zmeili, Rawan ^d   Derendorf, Hartmut ^b  

^a PRINCESS NOURAH BINT ABDULRAHMAN UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^d Riyadh Regional Laboratory   (Saudi Arabia)

Author keywords

ABCB1; CYP3A5; Pharmacokinetics; Polymorphisms; Quetiapine

Indexed keywords

QUETIAPINE; ABC TRANSPORTER SUBFAMILY B; ABCB1 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; NEUROLEPTIC AGENT;

ABCB1 GENE; ADULT; ARTICLE; CONTROLLED STUDY; CYP3A5 GENE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG RELEASE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MONTE CARLO METHOD; NORMAL HUMAN; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; TABLET; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; COMPUTER SIMULATION; CROSSOVER PROCEDURE; GENETICS; JORDAN; METABOLISM; MIDDLE AGED; NONLINEAR SYSTEM; PHARMACOGENETIC VARIANT; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; COMPUTER SIMULATION; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; JORDAN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NONLINEAR DYNAMICS; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUETIAPINE FUMARATE; YOUNG ADULT;

EID: 84942192226     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.172     Document Type: Article

References (23)

1. Gerlach M, Hunnerkopf R, Rothenhofer S, et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry. 2007; 40:72-76.
2. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004; 37:243-265.
3. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011; 44:195-235.
4. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007; 46:359-388.
5. Mauri MC, Volonteri LS, Fiorentini A, Pirola R, Bareggi SR. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother. 2007; 8:2207-2213.
6. Hiemke C, Dragicevic A, Grunder G, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit. 2004; 26:156-160.
7. Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009; 37:254-258.
8. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002; 71:163-169.
9. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations, correlation of one allele with P-glycoprotein expression, activity in vivo. Proc Natl Acad Sci USA. 2000; 97:3473-3478.
10. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001; 70:189-199.
11. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology. 2006; 187:415-423.
12. Nikisch G, Baumann P, Oneda B, et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol. 2011; 25:896-907.
13. Kim KA, Joo HJ, Lee HM, Park JY. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics. 2014; 24:35-42.
14. Sy SK, Heuberger J, Shilbayeh S, Conrado DJ, Derendorf H. A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation. AAPS J. 2013; 15:1189-1199.
15. Sy SK, Singh RP, Shilbayeh S, Zmeili R, Conrado D, Derendorf H. Influence of CYP3A5 6986A> G and ABCB1 3435C> T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. Clin Pharmacol Drug Dev. 2013; 2:67-78.
16. Patteet L, Maudens KE, Sabbe B, Morrens M, De Doncker M, Neels H. High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2014; 429:51-58.
17. de Kock L, Sy SK, Rosenkranz B, et al. The pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV co-Infected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother. 2014; 58:6242-6250.
18. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007; 34:711-726.
19. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008; 35:401-421.
20. Baumann P, Hiemke C, Ulrich S, et al. Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit. 2004; 26:167-170.
21. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry. 2000; 24:521-533.
22. Sy SK, Ciaccia A, et al. Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. Li W. 2002; 58:357-365.
23. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012; 92:366-375.